Weight Loss Medication: Latest Update
You may have heard that Tirzepatide, which you may also know as Mounjaro® or ‘the weight loss drug’, is now available from primary care. However, in the first two years entry criteria have been set by NHS England to allow safe entry of this repurposed medicine into the health system.
The eligibility criteria are as follows:
A BMI of 40 kg/m2 or higher (37.5 kg/m2 for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds) and at least four of these additional conditions, which will already have been diagnosed by your GP or another medical professional:
- Hypertension
- Dyslipidaemia
- Obstructive sleep apnoea
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Type 2 diabetes mellitus
For patients who meet the eligibility criteria above in discussion with the GP a decision will be made whether or not Tirzepatide is the best treatment for you. If it is agreed that Tirzepatide is the right choice you will also be required to agree to engage with behavioural support and wraparound care
Once more details are confirmed, all eligible patients will be contacted directly by the surgery team.
Please do not schedule an appointment or call to inquire about your eligibility and prescribing.
This notice will be updated as soon as further information becomes available.
Private supply:
More patients are now seeking to have weight loss injections prescribed privately. We are unable to discuss eligibility or suitability with you, and it is the responsibility of the private prescriber to discuss this with you. Please do not book an appointment to discuss this. Ensure you let the practice know if you are receiving these injections, so we can make note to ensure we are not prescribing medications that could interfere or cause problems with the injections.
Please see attached below the latest ‘Weight Management Service for Adults Policy’ from BLMK.